Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022

Rhea-AI Summary

Kamada Ltd. (NASDAQ: KMDA) is set to release its financial results for Q3 and the first nine months of 2022 on November 22, 2022, before U.S. markets open. Following the announcement, management will host a conference call at 8:30 AM ET to discuss the results. Investors can participate by phone or by joining a live webcast. Kamada specializes in plasma-derived therapeutics and has a diverse product portfolio including GLASSIA® and KEDRAB®. The company is focused on profitable growth and has a strong presence in the bio-pharmaceutical market.

Positive

• Kamada's diverse portfolio includes FDA-approved products such as GLASSIA® and KEDRAB®.
• The company has a robust pipeline, including an inhaled AAT product under clinical trial.
• Strong distribution network across over 30 countries enhances global reach.

Negative

• None.

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2022, prior to the open of the U.S. financial markets on Tuesday, November 22, 2022.

Kamada management will host an investment community conference call on Tuesday, November 22, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel) or 1 201-689-8263 (International) and entering the conference identification number: 13734312. The call will also be webcast live on the Internet at:
https://viavid.webcasts.com/starthere.jsp?ei=1582277&tp_key=8121e668e3.

The call will also be archived for 90 days on the Company’s website at www.kamada.com. 

About Kamada
Kamada Ltd. (the “Company”) is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma derived biopharmaceutical market. The Company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel through 2028. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will Kamada release its Q3 2022 financial results?

Kamada will release its Q3 2022 financial results on November 22, 2022.

What products does Kamada offer?

Kamada offers FDA-approved products like GLASSIA® and KEDRAB®, alongside several recently acquired plasma-derived products.

How can I participate in Kamada's financial results conference call?

Investors can participate in the conference call by dialing 1-877-407-0792 (U.S.) or joining the live webcast on Kamada's website.

What is Kamada's focus in the biopharmaceutical sector?

Kamada focuses on specialty plasma-derived therapeutics and has a diverse pipeline and product portfolio.